bruceine d has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Studies (bruceine d) | Trials (bruceine d) | Recent Studies (post-2010) (bruceine d) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
|---|---|---|---|---|---|
| 31 | 0 | 22 | 3,859 | 8 | 1,052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Ding, Q; Hao, Y; Kong, F; Tang, B; Yang, Y | 1 |
1 other study(ies) available for bruceine d and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; Inflammation; Male; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidative Stress; Parkinson Disease; Quassins; Signal Transduction | 2020 |